Bexsero | Description | MIMS Thailand

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing Local Product Insert

The information highlighted (if any) are the most recent updates for this brand.

Full Prescribing Info

Description

1 dose (0.5 ml) contains Recombinant Neisseria meningitidis group B NHBA fusion protein^{1, 2, 3} 50 micrograms, Recombinant Neisseria meningitidis group B NadA protein^{1, 2, 3} 50 micrograms, Recombinant Neisseria meningitidis group B fHbp fusion protein^{1, 2, 3}50 micrograms, Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 measured as amount of total protein containing the PorA P1.4² 25 micrograms.
¹produced in E. coli cells by recombinant DNA technology.
²Adsorbed on aluminium hydroxide (0.5 mg Al³⁺).
³NHBA (Neisserial Heparin Binding Antigen), NadA (Neisseria adhesin A), fHbp (factor H binding protein).
The vaccine is a white opalescent liquid suspension.
Excipients/Inactive Ingredients: Sodium chloride, Histidine, Sucrose, Water for injections.

Bexsero Description

vaccine, meningococcal

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma

Marketer:

GlaxoSmithKline